**ONLINE MUTATION REPORT**

*Spastin* gene mutation in Japanese with hereditary spastic paraplegia

I Yabe, H Sasaki, K Tashiro, T Matsuura, T Takegami, T Satoh


Hereditary spastic paraplegia (HSP) is a cluster of genetically heterogeneous disorders that has spastic paraplegia as the central feature. Autosomal dominant HSP (AD-HSP) is also genetically heterogeneous and seven loci have been identified so far on chromosomes 14q (SPG3), 2p (SPG4), 15q (SPG6), 8q (SPG8), 12q (SPG10), 19q (SPG12), and 2q (SPG13). Among them, the SPG4 gene named *spastin* (GenBank accession No AJ246001) has recently been identified; it is composed of 17 exons and encodes a putative nuclear protein member of the AAA (ATPases associated with diverse cellular activities) protein family. In the original report, five different mutations were identified in seven families.

HSP is a rare disorder in the Japanese population and the prevalence of SPG4 among Japanese AD-HSP patients is unknown. Only one Japanese family has been reported with an insertion mutation in exon 8 of *spastin*. In order to assess the frequency of *spastin* mutations in the Japanese, we analysed mutations in probands from 12 Japanese AD-HSP pedigrees.

**SUBJECTS AND METHODS**

All of the subjects were neurologically evaluated by the present authors. The diagnosis was based on the neurological findings, a progressive course with an insidious onset, and a positive family history indicating dominant inheritance. Neuroimaging studies were done to exclude other causes of spastic paraplegia. Among the subjects, one was a member of an HSP family that was previously reported to have 2p linked AD-HSP (maximum lod score 3.53).

All patients had progressive spasticity in the lower limbs bilaterally and their reflexes were hyperactive. All the patients showed an extensor plantar response. None of them showed extrapyramidal signs, ophthalmoplegia, retinal degeneration, skeletal muscle atrophy, or intellectual disturbance. Superficial sensation was intact, although some patients showed a slight reduction of vibration sensation. The mean age at onset was 35.3 years (SD 15.6, n=12), the range being 10-57 years. There was no significant difference in the mean age at onset between the probands with and without *spastin* mutation by Student’s *t* test (*p*=0.53).

**RESULTS**

Five of the 12 AD-HSP probands were found to have *spastin* gene mutations (table 1). The five mutations responsible for HSP included three missense mutations (R499C, Q347K, and K388R) and two splice site mutations (1370+1g→t and 1742-1g→t). The proband of the 2p linked family had no mutations in any of the exons or splice junction sites, 5′ upstream 4.8 kb region from the initiator ATG codon or the 3′ non-coding region from the stop codon to the polyadenylation site. In the subjects with *spastin* mutation, the mean age at onset was 31.8 years (SD 18.1, n=5), the range being 10-54 years. There was no significant difference in the mean age at onset between the probands with and without *spastin* mutation by Student’s *t* test (*p*=0.53).

**DISCUSSION**

The present study showed that five out of 12 probands with AD-HSP (41.6%) had *spastin* gene mutations. In the remaining AD-HSP probands (58.4%), such mutations were not detected. This is the first report on the frequency of *spastin* gene mutation among Japanese patients with AD-HSP. Three out of five mutations, including Q347K and the two splice site mutations, were novel mutations. Each of these novel mutations was segregating with affected members in each family (data not shown). The variety of mutations in our subjects indicates that each pedigree had a different founder.

Recently, Fonknechten et al analysed 17 exons of the *spastin* gene in 87 AD-HSP probands from around the world, but mainly from Europe. They reported that SPG4 accounted for 37% of all AD-HSP. Our estimation of the prevalence of SPG4 in Japanese AD-HSP patients is compatible with their finding.

As in previous reports, the three missense mutations that we found were localised within the functional domain of *spastin* (the AAA cassette) and were therefore considered to interfere with the functioning of *spastin*. Two splice site mutations were also detected in the present study. Fonknechten et al suggested that the frequency of *spastin* splice site mutations

---

**Table 1**

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Location</th>
<th>Mutation</th>
<th>Amino acid change</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>98-175</td>
<td>Exon 13</td>
<td>1620C→T</td>
<td>R499C</td>
<td>Missense</td>
</tr>
<tr>
<td>99-15</td>
<td>Intron 14</td>
<td>1742-1g→t</td>
<td></td>
<td></td>
</tr>
<tr>
<td>99-33</td>
<td>Exon 7</td>
<td>1164C→A</td>
<td>Q347K</td>
<td>Missense</td>
</tr>
<tr>
<td>99-116</td>
<td>Exon 8</td>
<td>1288A→G</td>
<td>K388R</td>
<td>Missense</td>
</tr>
<tr>
<td>99-175</td>
<td>Intron 9</td>
<td>1370+1g→t</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Amplified PCR products were purified with Microcon® (Amicon Inc, Beverly, MA, USA) and were sequenced directly using an ABI PRISM 377 DNA sequencing system (Applied Biosystems, Tokyo, Japan).

---

**DISCUSSION**

The present study showed that five out of 12 probands with AD-HSP (41.6%) had *spastin* gene mutations. In the remaining AD-HSP probands (58.4%), such mutations were not detected. This is the first report on the frequency of *spastin* gene mutation among Japanese patients with AD-HSP. Three out of five mutations, including Q347K and the two splice site mutations, were novel mutations. Each of these novel mutations was segregating with affected members in each family (data not shown). The variety of mutations in our subjects indicates that each pedigree had a different founder.

Recently, Fonknechten et al analysed 17 exons of the *spastin* gene in 87 AD-HSP probands from around the world, but mainly from Europe. They reported that SPG4 accounted for 37% of all AD-HSP. Our estimation of the prevalence of SPG4 in Japanese AD-HSP patients is compatible with their finding.

As in previous reports, the three missense mutations that we found were localised within the functional domain of *spastin* (the AAA cassette) and were therefore considered to interfere with the functioning of *spastin*. Two splice site mutations were also detected in the present study. Fonknechten et al suggested that the frequency of *spastin* splice site mutations

---
was significantly higher than in other human genetic disorders. These mutations are considered to be deleterious since the result is unstable aberrant transcripts that may lead to truncation or silencing of genes.

In the present study, we could not detect any specific mutation of the spastin gene in the proband of a 2p linked family. Svenson et al.15 and Fonknechten et al.16 also described similar cases where no mutation was detected in some 2p linked families. These findings may indicate that these AD-HSP cases where no mutation was detected in some 2p linked families. Further studies are needed to clarify the molecular mechanisms underlying SPG4.

ACKNOWLEDGEMENTS

We thank the AD-HSP patients for their participation in this study. This study was supported by a grant for Research on Ataxic Diseases from the Japanese Ministry of Health and Welfare.

Authors’ affiliations

1 Yabe, H Sasaki, K Tsujiro, Department of Neurology, Hokkaido University Graduate School of Medicine, N-15 W-7, Kitoko, Sapporo 060-8638, Japan
2 T Takegami, Department of Neurology, Baylor College of Medicine, Houston, USA
3 Matsuura, Department of Neurology, Tajimi City Hospital, Tajimi, Japan
4 Taot, Department of Neurology, Kasai City Hospital, Kasai, Japan
Correspondence to: Dr H Sasaki, Department of Neurology, Hokkaido University Graduate School of Medicine, N-15 W-7, Kitoko, Sapporo 060-8638, Japan; hsasaki@med.hokudai.ac.jp

REFERENCES


Spastin gene mutation in Japanese with hereditary spastic paraplegia

I Yabe, H Sasaki, K Tashiro, T Matsuura, T Takegami and T Satoh

*J Med Genet* 2002 39: e46
doi: 10.1136/jmg.39.8.e46

Updated information and services can be found at:
http://jmg.bmj.com/content/39/8/e46

These include:

**References**
This article cites 21 articles, 5 of which you can access for free at:
http://jmg.bmj.com/content/39/8/e46#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Molecular genetics (1254)
- Neuromuscular disease (257)
- Peripheral nerve disease (97)
- Ethics (220)
- Eye Diseases (298)
- Genetic screening / counselling (887)
- Immunology (including allergy) (604)
- Clinical genetics (257)
- JMG Online mutation reports (168)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/